HIVepsilon-seq-scalable characterization of intact persistent proviral HIV reservoirs in women
- PMID: 37843370
- PMCID: PMC10688329
- DOI: 10.1128/jvi.00705-23
HIVepsilon-seq-scalable characterization of intact persistent proviral HIV reservoirs in women
Abstract
The lack of a reliable method to accurately detect when replication-competent HIV has been cleared is a major challenge in developing a cure. This study introduces a new approach called the HIVepsilon-seq (HIVε-seq) assay, which uses long-read sequencing technology and bioinformatics to scrutinize the HIV genome at the nucleotide level, distinguishing between defective and intact HIV. This study included 30 participants on antiretroviral therapy, including 17 women, and was able to discriminate between defective and genetically intact viruses at the single DNA strand level. The HIVε-seq assay is an improvement over previous methods, as it requires minimal sample, less specialized lab equipment, and offers a shorter turnaround time. The HIVε-seq assay offers a promising new tool for researchers to measure the intact HIV reservoir, advancing efforts towards finding a cure for this devastating disease.
Keywords: HIV; HIV persistence; third-generation sequencing.
Conflict of interest statement
J.M.F., K.B., and M.A.S. have previously received travel expenses and research consumables from Oxford Nanopore Technologies. D.M.M. has provided consultancy to Merck Research Laboratories and ViiV Healthcare outside of this work and owns common stock in Gilead Sciences. A.A.A. has received funding from Merck and Gilead for consulting. Merck and Gilead have provided her institution with funding for her research. The remaining authors have no conflict to declare.
Figures
References
-
- Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong M, Lambotte O, Lamplough R, Ndung’u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR, International AIDS Society (IAS) Global Scientific Strategy working group . 2021. Research priorities for an HIV cure: international AIDS society global scientific strategy 2021. Nat Med 27:2085–2098. doi:10.1038/s41591-021-01590-5 - DOI - PubMed
-
- Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, Fray EJ, Beg SA, Antar AAR, Jenike KM, Bertagnolli LN, Capoferri AA, Kufera JT, Timmons A, Nobles C, Gregg J, Wada N, Ho YC, Zhang H, Margolick JB, Blankson JN, Deeks SG, Bushman FD, Siliciano JD, Laird GM, Siliciano RF. 2019. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566:120–125. doi:10.1038/s41586-019-0898-8 - DOI - PMC - PubMed
-
- Hiener B, Horsburgh BA, Eden J-S, Barton K, Schlub TE, Lee E, von Stockenstrom S, Odevall L, Milush JM, Liegler T, Sinclair E, Hoh R, Boritz EA, Douek D, Fromentin R, Chomont N, Deeks SG, Hecht FM, Palmer S. 2017. Identification of genetically intact HIV-1 proviruses in specific CD4(+) T cells from effectively treated participants. Cell Rep 21:813–822. doi:10.1016/j.celrep.2017.09.081 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
